iproniazid has been researched along with Cardiac Hypertrophy in 2 studies
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| MEERSON, FZ | 1 |
| ROZANOVA, LS | 1 |
| Master, AM | 1 |
2 other studies available for iproniazid and Cardiac Hypertrophy
| Article | Year |
|---|---|
[EFFECT OF CHANGES IN MEDIATOR METABOLISM ON THE DEVELOPMENT OF HEART HYPERTROPHY].
Topics: Aortic Coarctation; Aortic Valve Stenosis; Cardiomegaly; Catecholamines; Iproniazid; Monoamine Oxida | 1964 |
The Master two-step test.
Topics: Adolescent; Adult; Age Factors; Aged; Body Weight; Cardiomegaly; Coronary Disease; Electrocardiograp | 1968 |